BeOne Medicines $ONC
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS29
PHASE 3 / 2-315
RECRUITING17
READOUTS ≤12 MONTHS8
READOUT SLIPPED >6 MO33%
Delay Index: of 21 active trials registered more than a year ago, 7 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.0 months). See all sponsors →
Open BeOne Medicines on the live radar map → 📅 $ONC readout calendar (.ics)| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| Sonrotoclax NCT05471843 |
P1/2 | Active, not recruiting | Mantle Cell Lymphoma; Refractory Mantle Cell Lymphoma (MCL) | 125 | 2025-07-18 (+17 mo) |
| MANGROVE NCT04002297 |
P3 | Active, not recruiting | Mantle Cell Lymphoma; Non-Hodgkin Lymphoma | 510 | 2026-04-27 (+58 mo) |
| Sonrotoclax NCT05952037 |
P2 | Active, not recruiting | Waldenstrom Macroglobulinemia; Waldenstrom's Macroglobulinemia Recurrent | 114 | 2026-09-22 (-13 mo) |
| Sonrotoclax NCT04973605 |
P1/2 | Recruiting | Relapsed/Refractory Multiple Myeloma | 246 | 2026-11 (+38 mo) |
| Sonrotoclax NCT06637501 |
P2 | Active, not recruiting | Chronic Lymphocytic Leukemia | 94 | 2026-11 (-11 mo) |
| Zanubrutinib NCT04170283 |
P3 | Active, not recruiting | B-cell Malignancies | 955 | 2026-12-31 (+25 mo) |
| CaDAnCe-101 NCT05006716 |
P1/2 | Recruiting | B-cell Malignancy; Marginal Zone Lymphoma | 689 | 2027-03 (+38 mo) |
| BGB-B2033 NCT06427941 |
P1/2 | Recruiting | Metastatic Hepatocellular Carcinoma; Local Advanced Hepatocellular Carcinoma | 630 | 2027-03-31 (+5 mo) |
| Tacabrutideg NCT05294731 |
P1/2 | Recruiting | B-cell Malignancy; Non-Hodgkin Lymphoma | 146 | 2027-06-30 (+4 mo) |
| ALMOND NCT05707377 |
P2/3 | Active, not recruiting | Primary Membranous Nephropathy | 178 | 2027-10 (-14 mo) |
| Subcutaneous Tislelizumab NCT07043400 |
P3 | Recruiting | Metastatic Gastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma | 351 | 2027-10-30 |
| Tislelizumab NCT07733180 |
P2 | Recruiting | Advanced Esophageal Squamous Cell Carcinoma; Metastatic Esophageal Squamous Cell Carcinoma | 30 | 2028-02-28 |
| BGB-B2033 NCT07911683 |
P2 | Not yet recruiting | Hepatocellular Cancer; Liver Cancer | 100 | 2028-03-31 |
| Tacabrutideg NCT06973187 |
P3 | Recruiting | Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma | 500 | 2028-04-17 |
| CaDAnCe-302 NCT06846671 |
P3 | Recruiting | CLL; Chronic Lymphocytic Leukemia | 250 | 2028-05-15 |
| MAHOGANY NCT05100862 |
P3 | Active, not recruiting | Relapsed/Refractory Follicular Lymphoma; Marginal Zone Lymphoma | 799 | 2028-07 (+2 mo) |
| BGB-11417 NCT04771130 |
P1/2 | Recruiting | Acute Myeloid Leukemia; Myelodysplastic Syndromes | 260 | 2028-08-31 (+79 mo) |
| Sonrotoclax NCT06742996 |
P3 | Recruiting | Mantle Cell Lymphoma; B Cell Lymphoma | 300 | 2028-08-31 (-7 mo) |
| Tacabrutideg NCT06634589 |
P1/2 | Recruiting | B-cell Malignancy; Relapsed Cancer | 80 | 2028-12-02 |
| KANDELA-302 NCT07492641 |
P3 | Recruiting | HR+/HER2- Breast Cancer | 1056 | 2029-04 |
| BGB-B2033 NCT07836530 |
P3 | Recruiting | Hepatocellular Carcinoma; Liver Cancer | 492 | 2029-09-21 |
| Sonrotoclax NCT06943872 |
P3 | Recruiting | Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma | 630 | 2029-09-30 |
| CaDAnCe-303 NCT06970743 |
P3 | Active, not recruiting | Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma | 153 | 2029-11-30 |
| BG-C9074 NCT07811271 |
P3 | Not yet recruiting | Epithelial Ovarian Cancer; Fallopian Tube Cancer | 600 | 2029-11-30 |
| Sonrotoclax NCT06697184 |
P1/2 | Recruiting | Chronic Lymphocytic Leukemia; CLL | 258 | 2029-11-30 (+30 mo) |
| sonrotoclax NCT07770698 |
P1/2 | Not yet recruiting | Relapsed Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia | 30 | 2030-04-30 |
| Sonrotoclax NCT07277231 |
P3 | Recruiting | Chronic Lymphocytic Leukemia | 500 | 2031-02 |
| Tislelizumab NCT07554521 |
P2 | Recruiting | Advanced Unresectable Gastric Adenocarcinoma; Esophageal Squamous Cell Carcinoma | 30 | 2031-12-31 |
| Sonrotoclax NCT06073821 |
P3 | Active, not recruiting | CLL | 652 | 2032-02 |